Category: NASDAQ News

Altimmune (NASDAQ: ALT) Announces Positive Results from NasoVAX Extension Study

Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data […]

Continue Reading

Shineco, Inc. ( NASDAQ: TYHT) Establishes Subsidiary to Capture Industrial Cannabis Market Growth BEIJING, March. 18,

BEIJING, March. 18, 2019 /PRNewswire/ — Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and other health and well-being focused plant-based products in China, announced today that the Company has established a wholly owned subsidiary, Beijing Tenjove Newhemp Biotechnology Co., Ltd. (“TNB”) on March […]

Continue Reading

Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s ( Nasdaq: AKTX) Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON, March 13, 2019 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that it had […]

Continue Reading

Lipocine’s (LPCN) 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population

SALT LAKE CITY, March 12, 2019 /PRNewswire/ — Lipocine Inc. (LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders, today announced top-line results from the 16-week Liver Fat Imaging Study (“Liver Fat Study”) with LPCN 1144.  Previously, we announced eight-week top-line interim results on January 17, 2019. The Liver Fat Study was designed to assess the therapeutic potential […]

Continue Reading

ReWalk Announces 510k FDA Submission for ReStore™ Exo-Suit for Stroke Rehabilitation

ReWalk (NASDAQ: RWLK) Announces 510k FDA Submission for ReStore™ Exo-Suit for Stroke Rehabilitation Innovation in robotic rehabilitation technology will provide the first-of-its-kind medical device to rehab clinics nationwide, to treat the millions of patients with lower limb disability due to stroke PR Newswire MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Feb. 19, 2019 MARLBOROUGH, Mass. and YOKNEAM […]

Continue Reading

Facebook

Would you like to stay up to date with the latest small cap news?  Enter your email.